A prospective, non-randomized phase II trial of Trastuzumab and Capecitabine in patients with HER2 expressing metastasized pancreatic cancer

BACKGROUND: Pancreatic cancer is the fourth most common cause of cancer related death in Western countries. Advantages in surgical techniques, radiation and chemotherapy had almost no impact on the long term survival of affected patients. Therefore, the need for better treatment strategies is urgent...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Mihaljevic, Andre, Büchler, Peter, Harder, Jan, Hofheinz, Ralf, Gregor, Michael, Kanzler, Stephan, Schmiegel, Wolff, Heinemann, Volker, Endlicher, Esther, Klöppel, Günter, Seufferlein, Thomas, Geissler, Michael
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2009
Teme:
Study Protocol
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC2661037/
https://ncbi.nlm.nih.gov/pubmed/19133157
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2482-9-1
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki